Page 77 - Read Online

Page 20 of 25 Lue et al. J Cancer Metastasis Treat 2022;8:11 https://dx.doi.org/10.20517/2394-4722.2021.193

associated with survival. Blood 2009;114:2273-9. DOI PubMed PMC
28. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell
lymphoma patients treated with R-CHOP chemotherapy. Blood 2009;114:3533-7. DOI PubMed
29. Green TM, Nielsen O, de Stricker K, Xu-Monette ZY, Young KH, Møller MB. High levels of nuclear MYC protein predict the
presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol 2012;36:612-9. DOI PubMed
30. Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat
Rev Cancer 2017;17:223-38. DOI PubMed
31. Hiemcke-Jiwa LS, Minnema MC, Radersma-van Loon JH, et al. The use of droplet digital PCR in liquid biopsies: a highly sensitive
technique for MYD88 p.(L265P) detection in cerebrospinal fluid. Hematol Oncol 2018;36:429-35. DOI PubMed
32. Yamagishi Y, Sasaki N, Nakano Y, et al. Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of
central nervous system lymphoma. Cancer Sci 2021;112:4702-10. DOI PubMed PMC
33. Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large
B-cell lymphoma: a correlative biomarker study. The Lancet Oncology 2015;16:541-9. DOI PubMed PMC
34. Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-
throughput sequencing. Blood 2015;125:3679-87. DOI PubMed PMC
35. Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA.
Nat Biotechnol 2016;34:547-55. DOI PubMed PMC
36. Scherer F, Kurtz DM, Newman AM, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by
circulating tumor DNA. Sci Transl Med 2016;8:364ra155. DOI PubMed PMC
37. Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-Cell
lymphoma. J Clin Oncol 2018;36:2845-53. DOI PubMed PMC
38. Kurtz DM, Soo J, Co Ting Keh L, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in
circulating tumor DNA. Nat Biotechnol 2021;39:1537-47. DOI PubMed PMC
39. Récher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab
for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011;378:1858-67.
DOI PubMed
40. Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with
diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. The Lancet Oncology 2013;14:525-33. DOI
PubMed
41. Lugtenburg EJ, Brown P, van der Holt B, et al. Rituximab maintenance for patients with diffuse large B-cell lymphoma in first
complete remission: results from a randomized HOVON-Nordic lymphoma group phase III study. JCO 2019;37:7507-7507. DOI
42. Bartlett NL, Wilson WH, Jung SH, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-
Cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303. J Clin Oncol 2019;37:1790-9. DOI
PubMed PMC
43. Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in
previously untreated diffuse large B-Cell lymphoma. J Clin Oncol 2017;35:3529-37. DOI PubMed
44. Crump M, Leppä S, Fayad L, et al. Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving
remission after first-line therapy for high-risk diffuse large B-Cell lymphoma. J Clin Oncol 2016;34:2484-92. DOI PubMed
45. Thieblemont C, Tilly H, Gomes da Silva M, et al. Lenalidomide maintenance compared with placebo in responding elderly patients
with diffuse large B-Cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and
prednisone. J Clin Oncol 2017;35:2473-81. DOI PubMed
46. Witzig TE, Tobinai K, Rigacci L, et al. Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the
PILLAR-2 randomized phase III trial. Ann Oncol 2018;29:707-14. DOI PubMed
47. Leonard JP, Kolibaba KS, Reeves JA, et al. Randomized phase ii study of r-chop with or without bortezomib in previously untreated
patients with non-germinal center B-Cell-Like diffuse large B-Cell lymphoma. J Clin Oncol 2017;35:3538-46. DOI PubMed
48. Davies A, Cummin TE, Barrans S, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse
large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. The Lancet Oncology 2019;20:649-62. DOI
PubMed PMC
49. Younes A, Sehn LH, Johnson P, et al; PHOENIX investigators. Randomized phase III trial of ibrutinib and rituximab plus
cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-Cell diffuse large B-Cell lymphoma. J Clin
Oncol 2019;37:1285-95. DOI PubMed PMC
50. Nowakowski G, Hong F, Scott D, et al. Addition of lenalidomide to r-chop (R2chop) improves outcomes in newly diagnosed diffuse
large B-Cell lymphoma (DLBCL): first report of ecog-acrin1412 a randomized phase 2 us intergroup study of R2chop vs R-chop
Hematol Oncol 2019;37:37-8. DOI
51. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-Cell lymphoma. N Engl J Med
2022;386:351-63. DOI PubMed
52. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in
relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5. DOI PubMed
53. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in